Search icon
TCS, HDFCBANK, SBI Liquid Fund (G)
Senores Pharmaceuticals Ltd.

SENORES

Equity

BSE,NSE

Min. Investment

3,72,000.00

Open a free Demat account and invest in IPOs easily.

Download Orca

Google PlayApp Store

To access realtime data for GP Eco Solutions India Ltd. and use advance features for Applying IPO. Register or Login to Orca.

IPO Details

Bidding Dates

20 Dec 24 - 24 Dec 24

Price Range ₹

372 - 391

Total Equity

333.71Cr

Lot Size

38

Exchange Status

BSE,NSE

IPO Doc

Subscription Rate

Non-Institutional Investor

89.23×

Qualified Institutional Buyers

94.66×

Employees

19.92×

Retail Investors

89.23×

Total subscription Rate

93.41×

IPO Timeline

Offer start

20 Dec 2024

Offer end

24 Dec 2024

Allotment

26 Dec 2024

Refund initiation

27 Dec 2024

Demat transfer

27 Dec 2024

Listing

30 Dec 2024

About Company

Established in December 2017, Senores Pharmaceuticals Limited focuses on developing and manufacturing pharmaceutical products for regulated markets such as the US, Canada, and the UK, while also catering to emerging markets. The company's diverse product portfolio includes tablets and capsules across key therapeutic areas, such as antibiotics, anti-fungal treatments, and critical care medications. As of September 30, 2024, they have launched 55 products and established partnerships with distributors and hospitals across India. Senores operates three dedicated R&D facilities in India and the US, with a US FDA-approved manufacturing facility based in Ahmedabad, Gujarat. The company also manufactures APIs and critical care injectables, serving 43 countries in emerging markets. Its competitive strengths include a robust R&D capability, a specialized product portfolio tailored for regulated markets, and long-term marketing agreements with pharmaceutical companies in the US, Canada, and the UK. Backed by an experienced management team, the company is well-positioned for growth in both regulated and emerging markets.

Year Founded

26-12-2017

Promotor Details

Sanjay Shaileshbhai Majmudar

Promoter Holdings Details

ParticularPre-IPOPost-IPO
Percentage66.6745.76
Share Capital2217607921076079

Offer to Public

85,34,681.00 Cr

Highlights

  • Ability to serve regulated markets like the US, Canada, and the UK through a US FDA-approved manufacturing facility.
  • Distinct niche product portfolio developed in a short time for regulated markets.
  • Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the UK.
  • Presence in emerging markets with a strong portfolio, including specialty and complex products.
  • Strong R&D capabilities driving a differentiated product portfolio.

Challenges

  • Dependence on third-party marketing partners and distributors, with the risk of losing partners or facing financial instability, which could adversely affect business performance.
  • Reliance on the growth of regulated markets, with a potential decrease in market growth or failure to adapt to changes, negatively impacting operations and financial performance.
  • Risk of non-compliance with customer quality standards, leading to business loss, order cancellations, and warranty claims.
  • Dependence on a few key customers for revenue, with the risk of reduced demand or contract terminations affecting cash flows and business stability.
  • Negative cash flows from operating activities in recent fiscal years, potentially impacting future business operations and financial health.

Financials

YearsTotal AssetsShare CapitalProfit After TaxConsolidated Net ProfitAdjusted EPS
20231,310.5398.159.919.911.1336
2022587.0087.42327.08314.5510.3114
20246,069.24305.059.919.911.1336
Enrich money logo